Study identifies cognitive benefits of ketamine in patients with treatment-resistant depression

Which fac­tors deter­mine what we believe about our world, our­selves, our past, and our future? Cog­ni­tive neu­ro­science sug­gests that our beliefs are depen­dent on brain activ­i­ty, specif­i­cal­ly on the way our brains process sen­so­ry infor­ma­tion in order to make sense of our envi­ron­ment. These beliefs (defined as prob­a­bil­i­ty esti­mates) are cen­tral to our brain’s predictive…

Read More

FDA-approved, Cybin-sponsored clinicial trial to measure ketamine’s impact on the brain via Kernel Flow neuroimaging helmet

Kernel’s Brain-Imag­ing Hel­met Approved For Clin­i­cal Tri­al On Patients Using Ket­a­mine (Forbes): The U.S. Food and Drug Admin­is­tra­tion has approved a clin­i­cal tri­al using a neu­roimag­ing hel­met made by Los Ange­les-based Ker­nel to track what hap­pens in the brain when a human takes a psy­che­del­ic dose of ketamine.

Read More

Study: Psychedelics can promote neural plasticity in the prefrontal cortex and expand pathways for mental health

Psy­che­delics in Neu­rol­o­gy: Poten­tial for Improv­ing Neu­ro­plas­tic­i­ty (Neu­rol­o­gy­Times): “Back in the 1950s, research was prov­ing that psy­che­del­ic agents could be effec­tive in the treat­ment of var­i­ous neu­ropsy­chi­atric dis­or­ders. Unfor­tu­nate­ly, just as sci­ence was explor­ing their ben­e­fi­cial effects, the coun­ter­cul­ture was explor­ing and embrac­ing their effects. Slow­ly but sure­ly, psy­che­delics were asso­ci­at­ed with rebel­lious youth and…

Read More